openPR Logo
Press release

Urothelial Carcinoma Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2016 and Forecast 2017-2024

03-27-2018 03:53 PM CET | Health & Medicine

Press release from: Precision Business Insights

Urothelial Carcinoma Treatment Market

Urothelial Carcinoma Treatment Market

Market Outline: Global Urothelial Carcinoma Treatment Market
Urothelial carcinoma is also called as transitional cell carcinoma. Urothelial carcinoma is a type of cancer that occurs in the urinary system and it is most common type of bladder cancer of the ureter, urachus and urethra. Urothelial cell carcinoma starts from transitional epithelium. Potential signs in recognising the urothelial carcinoma include blood in urine, persistent back pain and painful urination. Generally, urothelial cell carcinoma is diagnosed using the blood tests and scanning. Treatment may include anticancer drugs, antibacterials to reduce or stop the growth of cancer cells and other treatments such as radiotherapy or nephroureterectomy are indicated.

Market Dynamics: Urothelial Carcinoma Treatment Market
Urothelial carcinoma treatment market is driven by the increase in global prevalence of the bladder cancer and emergence of potential diagnostics for identifying bladder cancer. Furthermore, increase funding for R&D activities to develop new cancer therapies and growing awareness regarding early diagnosis of cancer as a result of awareness programs or other initiatives by government and non-government organizations are expected to boost the urothelial carcinoma treatment market over the forecast period. However, high cost of R&D for development of new drugs and presence of generic drugs in the market are expected to hamper the market revenue growth during the forecast period.


A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/urothelial-carcinoma-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

Market Scope: Urothelial Carcinoma Treatment Market
Global urothelial carcinoma treatment market is segmented based on type of treatment, and distribution channel
Based on treatment, it segmented into
• Immunotherapy
• Radiotherapy
• Chemotherapy
• Others
Based on distribution channel, it is segmented into
• Hospital Pharmacies
• Retail Pharmacies
• Others

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/urothelial-carcinoma-treatment-market/#ulp-c654SbFYO64MsOhu


Market Summary: Urothelial Carcinoma Treatment Market
Global urothelial carcinoma treatment market growth is driven by increase in global prevalence rate of bladder cancer. According to World Cancer Research Fund International, bladder cancer is the ninth most common cancer in the world and in the year 2012 – 430,000 new cases were diagnosed. The market has many large players and actively developing and launching of new products related to urothelial carcinoma treatment. For instance, in March 2017, Bavarian Nordic A/S collaborated with F.Hoffmann-La Roche Ltd to evaluate the Tecentriq and CV301 drugs in urothelial cancer treatment. Furthermore, promising pipeline drugs for treatment of urothelial carcinoma such as B-701 (in phase 2 clinical trials by BioClin Therapeutics, FGFR-3 Antibody (By Eli Lilly and Company in phase 1 clinical trials) are expected to boost future revenue forecasts.

Region Analysis: Urothelial Carcinoma Treatment Market
Geographically, urothelial carcinoma treatment market has been segmented into Latin America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America expected to grow at significant rates owing to growing prevalence of bladder cancer, increase in awareness and well-established healthcare infrastructure. American Cancer Society estimates that, about 79,030 new cases of bladder cancer in 2017 in U.S. alone. Europe region expected to grow at notable rates owing to the factors such as growing awareness related to early diagnosis of cancer and developed healthcare infrastructure coupled with prevalence rates of urothelial cancer. Asia Pacific region is expected exhibit significant growth opportunity owing to developing healthcare infrastructure and low R&D costs.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/urothelial-carcinoma-treatment-market/#ulp-14mlyhjMGhVjZqa3


Market Participants: Urothelial Carcinoma Treatment Market
Some of the players in Market are GlaxoSmithKline plc (U.K.), Genentech, Inc. (U.S.), Novartis AG (Switzerland), Dendreon (U.S.), Merck KGaA (Germany), Eisai Co. (Japan), Sanofi S.A. (France), and Bristol-Myers Squibb (U.S.) to name a few

Notable Market Developments: Urothelial carcinoma Treatment Market
• In May 2017, U.S. Food and Drug Administration approved Sereno Inc.’s (E. Merck KG) BAVENCIO (avelumab) for the treatment of urothelial carcinoma.
• In February 2017, U.S. FDA has approved Bristol-Mayer Squibb Company’s OPDIVO (Nivolumab) for the treatment of urothelial carcinoma.


Key Features of the Report
• The report provides granular level information about The market size, regional market share and forecast from 2017-2024
• The report covers in-detail insights about The competitor’s overview, key findings and Their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by The industry
• The report tracks recent innovations, key developments and startup’s details that are working in The industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/urothelial-carcinoma-treatment-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Urothelial Carcinoma Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2016 and Forecast 2017-2024 here

News-ID: 994767 • Views: 622

More Releases from Precision Business Insights

Polyurethane Adhesives Market Was Valued at USD 6,867.9 million in 2021, Owing t …
According to Precision Business Insights (PBI) latest report the global polyurethane adhesives market is valued at USD 6,867.9 million in 2021. Global polyurethane adhesives market segmented into following types: By Resin type (Thermoset, and Thermoplastic), By Technology (Solvent-Borne, Hot Melt, Reactive, Water Borne, and Rad-cure), By End user (Automotive, Building & Construction, Electrical & Electronics, Footwear, Furniture, Packaging, and Others) and Geography (North America, Europe, Asia-Pacific, Latin America, and MEA)
Waterproofing Membranes Market Was Valued at USD 21,473.7 million in 2021 Owing …
According to Precision Business Insights (PBI) latest report the global waterproofing membranes market is valued at USD 21,473.7 million in 2021. Global waterproofing membranes market segmented into following types By Product (Polyvinyl Chloride (PVC), Bitumen, TPO, Ethylene Propylene Diene Monomer (EPDM), Others), By Application (Building Structures, Tunnels & Landfills, Roofing & Walls, Bridges & Highways, Others), By Type (Liquid Applied Membranes, Sheet Based Membranes) and Geography (North America, Europe, Asia-Pacific,
Atrial Fibrillation Market Was Valued at USD 1,945.6 million in 2021 Owing to In …
According to Precision Business Insights (PBI) latest report the global atrial fibrillation market is valued at USD 1,945.6 million in 2021. Global atrial fibrillation market segmented into following types: By Type (Surgical, and Non-Surgical), By Technology (Radiofrequency, Laser, Cryotherapy, and Others), By End user (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East Africa) Forecast to 2028. Key player's profiles in the atrial
Bone Substitute And Allograft Bone Market Size, Scope, Growth, Competitive Analy …
Precision Business Insights published a research report on "Bone Substitutes and Bone Allografts Market By Product Type (Bone Substitutes and Bone Allografts), By Bone Substitute Type (Hydroxyapatite (Hap), Calcium Phosphate, Calcium Sulphate, Bioactive Glass), By Bone Allograft Type (Freeze Dried and Demineralized Bone Matrix) - Global/Region/Country Forecast to 2028" Bone grafts and substitutes are used to replace missing bones and to treat fractures. They are made up of an osteoconductive matrix

All 5 Releases


More Releases for Urothelial

Urothelial Cancer Drugs Market Report Up to 2031
Visongain has published a new report on Urothelial Cancer Drugs Market Report 2021-2031: Forecasts by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma), by Treatment (Chemotherapy, Immunotherapy). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Global Urothelial Cancer Drugs market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx
Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sacituzumab Govitecan (from Gilead Sciences) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugated to a topoisomerase I inhibitor (SN-38). Trop-2 receptor, a protein frequently expressed in multiple types
Urothelial Cancer Drugs - Product Modifications 2028 | Market AstraZeneca, Merck
Global Urothelial Cancer Drugs Market: Overview Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder which can spread to other parts of the body. The urothelium comprises of the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. All those comprise of the urothelial cells, or transitional cells. Urothelial carcinoma is the most widespread bladder cancer. It
Urothelial Cancer Drugs Market - Players largest contributor 2028 | Roche, Astra …
Global Urothelial Cancer Drugs Market: Overview Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder which can spread to other parts of the body. The urothelium comprises of the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. All those comprise of the urothelial cells, or transitional cells. Urothelial carcinoma is the most widespread bladder cancer. It
Urothelial Carcinoma Treatment Market to Record Study Growth by 2024
Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma
Urothelial Carcinoma Diagnostics Market Forecast over 2017 – 2025
Urothelial Carcinoma or Transitional Cell Carcinoma encompasses cancer in different parts of urinary tract like kidney, bladder, ureters, and renal pelvis. Bladder tumors account for 90-95% of urothelial carcinoma. Urothelial Carcinoma occur more commonly in men than in women with the ratio of 3:1. Tobacco smoking, Coffee drinking, analgesic abuse, some occupational exposures are the factors that promote urothelial carcinoma. The urothelial carcinoma diagnosis involves the tests that are used